Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

ICON3 trial results have suggested that CAP and carboplatin–taxol regimens as first-line treatment of advanced ovarian cancer (AOC) yield similar survival. We explored the impact of increased dose of cyclophosphamide in a modified CAP regimen on the disease-free survival (DFS) and overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray-Coquard, I, Paraiso, D, Guastalla, J-P, Leduc, B, Guichard, F, Martin, C, Chauvenet, L, Haddad-Guichard, Z, Lepillé, D, Orfeuvre, H, Gautier, H, Castera, D, Pujade-Lauraine, É
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360456/
https://www.ncbi.nlm.nih.gov/pubmed/17923867
http://dx.doi.org/10.1038/sj.bjc.6604026

Ejemplares similares

Ejemplares similares